Provectus Receives 4th Pharmaceutical Patent for Anti-Cancer Agents
31st Jan 2006, 14:38 GMT
Provectus Pharmaceuticals announced it has received the Company's fourteenth US patent, which is its 4th US patent for its pharmaceutical products.
Provectus Receives 4th Pharmaceutical Patent for Anti-Cancer Agents related news:
- Advancis Pharmaceutical Appoints R. Gordon Douglas, M.D. Chairman of the Board — RedOrbit News - Health
- Genesis Bioventures Announces Breast Cancer Marker Receives Diagnostic and Therapeutic Patent Approval — RedOrbit News - Health
- Fortinet settles anti-virus patent dispute — Channel Register - Security
- Results show Genta's cancer drug is effective — Pharmaceutical Business Review Online Latest News
- Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice — British Journal of Cancer AOP
- Ventegra Receives Coverage in Drug Benefit News — PR Web (The Free Wire Service) Industry Healthcare
- GSK drug approved in Europe for lung cancer — Pharmaceutical Business Review Online Latest News
- Last NTP Patent Tentatively Thrown Out — Slashdot: Your Rights Online
- Forgent Patent to Be Reviewed — WSJ.com: What's News US
- UK Patent Office Will Handicap Your Odds In A Lawsuit For 200 Quid — Techdirt